Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2023 Filed Feb 28, 2023 21:47 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 4,714 | $289.12 | $1,362,911.68 |
DisclosureSEC source: 0001209191-23-013708 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,590 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:50 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 3,308 | $289.12 | $956,408.96 |
DisclosureSEC source: 0001209191-23-013713 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,207 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:53 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 9,386 | $289.12 | $2,713,680.32 |
DisclosureSEC source: 0001209191-23-013718 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,969 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:57 UTC |
LEIDEN JEFFREY MDirector · Executive Chairman
|
Tax withholdingCommon Stock | 13,730 | $289.12 | $3,969,617.60 |
DisclosureSEC source: 0001209191-23-013728 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,349 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:02 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 2,468 | $289.12 | $713,548.16 |
DisclosureSEC source: 0001209191-23-013744 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,518 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:09 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 3,970 | $289.12 | $1,147,806.40 |
DisclosureSEC source: 0001209191-23-013757 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,014 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:11 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 3,308 | $289.12 | $956,408.96 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,159 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:14 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 3,308 | $289.12 | $956,408.96 |
DisclosureSEC source: 0001209191-23-013774 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,133 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:06 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 200 | $296.31 | $59,262.00 |
DisclosureSEC source: 0001209191-23-012672 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,304 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $296.31 (range $296.20 to $296.41). Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:06 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 394 | $295.38 | $116,379.72 |
DisclosureSEC source: 0001209191-23-012672 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,504 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $295.38 (range $294.83 to $295.72). Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:06 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 1,378 | $294.29 | $405,531.62 |
DisclosureSEC source: 0001209191-23-012672 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,898 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $294.29 (range $293.83 to $294.82). Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:06 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 300 | $292.86 | $87,858.00 |
DisclosureSEC source: 0001209191-23-012672 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,276 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $292.86 (range $292.44 to $293.37). Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:06 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 129 | $291.84 | $37,647.36 |
DisclosureSEC source: 0001209191-23-012672 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,576 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $291.84 (range $291.17 to $292.03). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 900 | $294.73 | $265,257.00 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,246 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $294.73 (range $294.47 to $295.37). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,843 | $294.03 | $541,897.29 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,146 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $294.03 (range $293.45 to $294.42). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,223 | $292.76 | $358,045.48 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,989 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $292.76 (range $292.25 to $293.12). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:25 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 36 | $291.01 | $10,476.36 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,212 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:30 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 736 | $294.58 | $216,810.88 |
DisclosureSEC source: 0001209191-23-011665 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,705 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $294.58 (range $294.36 to $294.96). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:30 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 1,100 | $293.74 | $323,114.00 |
DisclosureSEC source: 0001209191-23-011665 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,441 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $293.74 (range $293.30 to $294.19). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:30 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 545 | $292.77 | $159,559.65 |
DisclosureSEC source: 0001209191-23-011665 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,541 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $292.77 (range $292.25 to $293.07). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:30 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 21 | $291.01 | $6,111.21 |
DisclosureSEC source: 0001209191-23-011665 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,086 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 124 | $294.77 | $36,551.48 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,467 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 207 | $293.83 | $60,822.81 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,591 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 145 | $292.85 | $42,463.25 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,798 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36). Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:48 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 4 | $291.01 | $1,164.04 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,943 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:25 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011655 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,248 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:30 UTC |
Arbuckle Stuart AEVP, COO
|
Tax withholdingCommon Stock | 4,498 | $292.85 | $1,317,239.30 |
DisclosureSEC source: 0001209191-23-011665 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,107 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:32 UTC |
Bozic CarmenEVP and CMO
|
Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011680 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,515 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:35 UTC |
Kewalramani ReshmaDirector · CEO & President
|
Tax withholdingCommon Stock | 9,359 | $292.85 | $2,740,783.15 |
DisclosureSEC source: 0001209191-23-011686 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,355 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:43 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Tax withholdingCommon Stock | 3,498 | $292.85 | $1,024,389.30 |
DisclosureSEC source: 0001209191-23-011699 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,986 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:46 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011701 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,984 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:48 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
Tax withholdingCommon Stock | 4,498 | $292.85 | $1,317,239.30 |
DisclosureSEC source: 0001209191-23-011704 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,947 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:50 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011707 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,441 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 308 | $301.02 | $92,714.16 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,998 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $301.02 (range $300.79 to $301.22). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,888 | $300.11 | $566,607.68 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,306 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $300.11 (range $299.76 to $300.70). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,165 | $299.08 | $647,508.20 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,194 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $299.08 (range $298.71 to $299.54). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 395 | $297.97 | $117,698.15 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,359 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $297.97 (range $297.50 to $298.35). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 842 | $296.85 | $249,947.70 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,754 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.42 to $297.37). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 800 | $295.79 | $236,632.00 |
DisclosureSEC source: 0001209191-23-010045 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,596 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $295.79 (range $295.31 to $296.12). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:14 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 400 | $300.89 | $120,356.00 |
DisclosureSEC source: 0001209191-23-010050 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,605 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $300.89 (range $300.78 to $301.03). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:14 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 1,734 | $300.09 | $520,356.06 |
DisclosureSEC source: 0001209191-23-010050 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,005 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $300.09 (range $299.73 to $300.70). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:14 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 2,003 | $299.13 | $599,157.39 |
DisclosureSEC source: 0001209191-23-010050 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,739 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $299.13 (range $298.68 to $299.60). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:14 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 560 | $298.14 | $166,958.40 |
DisclosureSEC source: 0001209191-23-010050 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,742 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $298.14 (range $297.59 to $298.57). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:14 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 901 | $296.85 | $267,461.85 |
DisclosureSEC source: 0001209191-23-010050 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,302 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $296.85 (range $296.49 to $297.30). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:14 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 800 | $295.84 | $236,672.00 |
DisclosureSEC source: 0001209191-23-010050 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,203 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $295.84 (range $295.34 to $296.20). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:16 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 279 | $301.11 | $84,009.69 |
DisclosureSEC source: 0001209191-23-010055 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,734 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:16 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 1,902 | $300.29 | $571,151.58 |
DisclosureSEC source: 0001209191-23-010055 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,013 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 51 | $300.58 | $15,329.58 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 5 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,445 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 135 | $299.60 | $40,446.00 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,496 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16). Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 21:18 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 43 | $297.98 | $12,813.14 |
DisclosureSEC source: 0001209191-23-010061 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,631 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.